{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T20:43:14Z","timestamp":1794688994023,"version":"4.9.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Systemic sclerosis (scleroderma, SSc) is a rare multisystem autoimmune disease characterized by autoantibodies, vasculopathy, and fibrosis of the skin and internal organs. This review aims to provide an overview and summary of the recent epidemiological studies in systemic sclerosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Global trends of scleroderma demonstrate greater prevalence of SSc in European, North, and South American patients compared with East Asian patients. However, the greatest prevalence (47 in 100\u200a000), was found among the indigenous peoples in Canada. Phenotypical differences exist depending on the age of presentation with greater internal organ involvement and disease acceleration present in older patients. Sex differences include greater severity of disease expression, relative prevalence of diffuse cutaneous SSc, and organ involvement in males versus females. New studies conflict with previous data reporting greater proportion of pulmonary arterial hypertension in females. Furthermore, the effect of low median household income is demonstrated as a factor increasing risk of death in SSc patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Understanding the epidemiological factors in SSc enables patient care through patient classification, prognostication, and monitoring. Future research may emphasize enrichment of SSc patients in randomized trials who are more likely to progress or be treatment responsive, focused screening, and personalized patient care through the creation and validation of new SSc criteria and subsets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000785","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T15:52:50Z","timestamp":1611244370000},"page":"122-127","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":53,"title":["Scleroderma epidemiology update"],"prefix":"10.1097","volume":"33","author":[{"given":"Leonardo Martin","family":"Calderon","sequence":"first","affiliation":[{"name":"Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, St. Joseph's Healthcare, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"530","DOI":"10.12968\/hmed.2019.80.9.530","article-title":"Systemic sclerosis","volume":"80","author":"Hughes","year":"2019","journal-title":"Br J Hosp Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"875","DOI":"10.17219\/acem\/64334","article-title":"Systemic sclerosis sine scleroderma","volume":"26","author":"Kucharz","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.semarthrit.2008.06.002","article-title":"Determinants of morbidity and mortality of systemic sclerosis in Canada","volume":"39","author":"Al-Dhaher","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.24676","article-title":"Health-related quality of life in systemic sclerosis: a systematic review","volume":"61","author":"Hudson","year":"2009","journal-title":"Arthritis Care Res"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40274-019-6409-1","article-title":"Interstitial lung disease in systemic sclerosis large burden","volume":"842","author":"Morrisroe","year":"2019","journal-title":"Pharmacoecon Outcomes News"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12890-019-0989-1","article-title":"The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia","volume":"19","author":"Morrisroe","year":"2019","journal-title":"BMC Pulm Med"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5301\/jsrd.5000209","article-title":"Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes","volume":"1","author":"Peoples","year":"2016","journal-title":"J Scleroderma Related Disord"},{"issue":"(Suppl 4)","key":"R11-20250526","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/ard.50.Suppl_4.846","article-title":"Epidemiology of scleroderma","volume":"50","author":"Silman","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis Rheum"},{"key":"R13-20250526","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"Van Den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11926-015-0506-3","article-title":"New ACR EULAR guidelines for systemic sclerosis classification","volume":"17","author":"Johnson","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/1756-185X.13716","article-title":"Prevalence and incidence of systemic sclerosis: a systematic review and meta-analysis","volume":"22","author":"Zhong","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/03009742.2018.1459830","article-title":"Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database","volume":"48","author":"Carreira","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/rheumatology\/keaa127","article-title":"Older age onset of systemic sclerosis\u2013accelerated disease progression in all disease subsets","volume":"59","author":"Moinzadeh","year":"2020","journal-title":"Rheumatology"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"102602","DOI":"10.1016\/j.autrev.2020.102602","article-title":"Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)","volume":"19","author":"Jiang","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"102494","DOI":"10.1016\/j.autrev.2020.102494","article-title":"Gender-related differences in systemic sclerosis","volume":"19","author":"Hughes","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.semarthrit.2019.07.007","article-title":"Sex hormones and sex hormone-targeting therapies in systemic sclerosis: a systematic literature review","volume":"50","author":"Ciaffi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-019-1870-6","article-title":"Estradiol levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival","volume":"21","author":"Frost","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.berh.2010.10.007","article-title":"Epidemiology of systemic sclerosis","volume":"24","author":"Nikpour","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","article-title":"Geoepidemiology of systemic sclerosis","volume":"9","author":"Ranque","year":"2010","journal-title":"Autoimmun Rev"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/acr.23861","article-title":"Increased morbidity and mortality of scleroderma in African Americans compared to non\u2013African Americans","volume":"71","author":"Moore","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.autrev.2018.11.001","article-title":"Systemic sclerosis and exposure to heavy metals","volume":"18","author":"Marie","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CLEP.S191418","article-title":"Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease","volume":"11","author":"Bergamasco","year":"2019","journal-title":"Clin Epidemiol"},{"key":"R28-20250526","first-page":"3","article-title":"One year in review 2020: systemic sclerosis","volume":"38","author":"Orlandi","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00393-018-0492-8","article-title":"Overall and sex-and disease subtype-specific mortality in patients with systemic sclerosis","volume":"78","author":"Lee","year":"2019","journal-title":"Zeitsch Rheumatol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","article-title":"Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis","volume":"78","author":"Becker","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R32-20250526","first-page":"241246","article-title":"Limited cutaneous systemic sclerosis: the unfairly neglected subset","volume":"1","author":"Allanore","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.autrev.2019.102452","article-title":"Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the EUSTAR database","volume":"19","author":"Frantz","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R34-20250526","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/BOR.0000000000000747","article-title":"Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors","volume":"32","author":"Sobanski","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"102515","DOI":"10.1016\/j.autrev.2020.102515","article-title":"Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels","volume":"19","author":"Smeets","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"(Suppl 3)","key":"R37-20250526","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.5152\/eurjrheum.2020.19116","article-title":"Systemic sclerosis: to subset or not to subset, that is the question","volume":"7","author":"Johnson","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"102659","DOI":"10.1016\/j.autrev.2020.102659","article-title":"Undifferentiated connective tissue disease at risk for systemic sclerosis: which patients might be labeled prescleroderma?","volume":"19","author":"Valentini","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1073\/pnas.1906593116","article-title":"HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry","volume":"117","author":"Gourh","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun Rev"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:22:04Z","timestamp":1748280124000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000785","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]}}}